PortfoliosLab logoPortfoliosLab logo
RXST vs. IDYA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RXST vs. IDYA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RXST achieves a -52.59% return, which is significantly lower than IDYA's -19.38% return.


RXST

1D
-5.73%
1M
-33.24%
YTD
-52.59%
6M
-57.99%
1Y
-68.19%
3Y*
-42.53%
5Y*
10Y*

IDYA

1D
-3.70%
1M
-1.14%
YTD
-19.38%
6M
-17.28%
1Y
31.34%
3Y*
3.87%
5Y*
6.44%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

RXST vs. IDYA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
RXST
RxSight, Inc.
-52.59%-69.69%-14.73%218.23%12.62%-29.69%
IDYA
IDEAYA Biosciences, Inc.
-19.38%34.51%-27.77%95.82%-23.14%-3.51%

Correlation

The correlation between RXST and IDYA is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Aug 2, 2021

0.30

Fundamentals

Market Cap

RXST:

$204.05M

IDYA:

$2.47B

EPS

RXST:

-$1.14

IDYA:

-$1.58

PS Ratio

RXST:

1.59

IDYA:

10.99

PB Ratio

RXST:

0.76

IDYA:

2.64

Total Revenue (TTM)

RXST:

$127.48M

IDYA:

$225.27M

Gross Profit (TTM)

RXST:

$98.18M

IDYA:

$215.25M

EBITDA (TTM)

RXST:

-$50.09M

IDYA:

-$157.90M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RXST vs. IDYA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXST
RXST Risk / Return Rank: 55
Overall Rank
RXST Sharpe Ratio Rank: 66
Sharpe Ratio Rank
RXST Sortino Ratio Rank: 66
Sortino Ratio Rank
RXST Omega Ratio Rank: 66
Omega Ratio Rank
RXST Calmar Ratio Rank: 22
Calmar Ratio Rank
RXST Martin Ratio Rank: 55
Martin Ratio Rank

IDYA
IDYA Risk / Return Rank: 6363
Overall Rank
IDYA Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
IDYA Sortino Ratio Rank: 5959
Sortino Ratio Rank
IDYA Omega Ratio Rank: 5757
Omega Ratio Rank
IDYA Calmar Ratio Rank: 6868
Calmar Ratio Rank
IDYA Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXST vs. IDYA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


RXSTIDYADifference

Sharpe ratio

Return per unit of total volatility

-0.93

0.69

-1.62

Sortino ratio

Return per unit of downside risk

-1.46

1.27

-2.73

Omega ratio

Gain probability vs. loss probability

0.81

1.15

-0.34

Calmar ratio

Return relative to maximum drawdown

-0.98

1.52

-2.51

Martin ratio

Return relative to average drawdown

-1.49

3.57

-5.07

RXST vs. IDYA - Sharpe Ratio Comparison

The current RXST Sharpe Ratio is -0.93, which is lower than the IDYA Sharpe Ratio of 0.69. The chart below compares the historical Sharpe Ratios of RXST and IDYA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


RXSTIDYADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.93

0.69

-1.62

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.11

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.31

0.19

-0.50

Drawdowns

RXST vs. IDYA - Drawdown Comparison

The maximum RXST drawdown since its inception was -92.32%, which is greater than IDYA's maximum drawdown of -74.64%. Use the drawdown chart below to compare losses from any high point for RXST and IDYA.


Loading charts...

Drawdown Indicators


RXSTIDYADifference

Max Drawdown

Largest peak-to-trough decline

-92.32%

-74.64%

-17.68%

Max Drawdown (1Y)

Largest decline over 1 year

-68.75%

-26.39%

-42.36%

Max Drawdown (3Y)

Largest decline over 3 years

-92.32%

-69.23%

-23.09%

Max Drawdown (5Y)

Largest decline over 5 years

-69.42%

Current Drawdown

Current decline from peak

-92.32%

-40.87%

-51.45%

Average Drawdown

Average peak-to-trough decline

-36.57%

-30.95%

-5.62%

Ulcer Index

Depth and duration of drawdowns from previous peaks

45.29%

11.23%

+34.06%

Volatility

RXST vs. IDYA - Volatility Comparison

RxSight, Inc. (RXST) has a higher volatility of 20.76% compared to IDEAYA Biosciences, Inc. (IDYA) at 8.22%. This indicates that RXST's price experiences larger fluctuations and is considered to be riskier than IDYA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RXSTIDYADifference

Volatility (1M)

Calculated over the trailing 1-month period

20.76%

8.22%

+12.54%

Volatility (6M)

Calculated over the trailing 6-month period

44.14%

30.77%

+13.37%

Volatility (1Y)

Calculated over the trailing 1-year period

73.67%

46.05%

+27.62%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

69.13%

58.97%

+10.16%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

69.13%

73.86%

-4.73%

Dividends

RXST vs. IDYA - Dividend Comparison

Neither RXST nor IDYA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RXST vs. IDYA - Financials Comparison

This section allows you to compare key financial metrics between RxSight, Inc. and IDEAYA Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
30.89M
6.56M
(RXST) Total Revenue
(IDYA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


RXST and IDYA have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

RXST has higher volatility (20.76%) compared to IDYA (8.22%). In terms of maximum drawdown, RXST dropped -92.32% vs IDYA's -74.64%.

IDYA currently has the higher Sharpe Ratio (0.69 vs -0.93), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RXST and IDYA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer